High-throughput TCR repertoire-based platforms for antigen-specific cancer immunotherapy
Technical Report,01 Aug 2019,31 Jul 2020
The University of Kansas Center for Research, Inc. Lawrence United States
Pagination or Media Count:
We seek to develop new platform technologies that will help us to better understand why and how immune-based cancer treatments are effective, and to apply that fundamental knowledge to develop rapid, targeted cancer therapeutics and improve cancer care. Modern immune-based therapies have shown tremendous success for treating many different kinds of cancers, and T cells play a critical role in these treatments because they have a unique ability to specifically target and selectively destroy tumor cells. However, T cells are difficult to analyze in the laboratory because each T cell has multiple unique genes, and thus each T cell must be studied one cell at a time. In the prior reporting period, we have made progress toward establishing these new systems using both control TCRs and with patient immune libraries. We are excited to apply these technologies to understand the mechanistic features of cancer-specific T cell targeting, and apply that information to develop more precise and effective cancer therapeutics in future reporting periods.
- Medicine and Medical Research